FGP
SRPT icon

Freestone Grove Partners’s Sarepta Therapeutics SRPT Stock Holding History

Freestone Grove Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.38M Buy
76,629
+69,709
+1,007% +$1.32M 0.01% 484
2026
Q1 		$151K Buy
+6,920
New +$134K ﹤0.01% 765
2025
Q4 		– Sell
-18,515
Closed -$357K – 932
2025
Q3 		$357K Buy
+18,515
New +$330K ﹤0.01% 588

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Freestone Grove Partners's SRPT Position: Q2 2026 in Review

Freestone Grove Partners increased its Sarepta Therapeutics (SRPT) stake by 1,007% in Q2 2026, buying an estimated $1.32M and bringing the position to 76,629 shares worth $1.38M. The position accounts for 0.01% of the portfolio, ranked #484.

Freestone Grove Partners first reported a position in SRPT in Q3 2025 and has held it in 3 quarters since. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Freestone Grove Partners held 76,629 shares of Sarepta Therapeutics worth $1.38M as of Q2 2026.
  • Freestone Grove Partners bought 69,709 Sarepta Therapeutics shares in Q2 2026, an estimated $1.32M.
  • Sarepta Therapeutics made up 0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #484 holding.
  • Freestone Grove Partners first reported a position in Sarepta Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.